2015 American Transplant Congress » Poster Session A: Liver: Immunosuppression and Rejection

Date: Saturday, May 2, 2015

Time: 5:30pm-7:30pm

Location: Exhibit Hall E

Session Type: Poster Session

Meeting: 2015 American Transplant Congress

5:30pm-7:30pm: Basiliximab Induction With Delayed Tacrolimus Initiation up to 14 Days Post Liver Transplantation Maintains Excellent Clinical Outcomes While Preserving Renal Function

J. Werth, W. Ally, D. Maluf, S. Pelletier.

5:30pm-7:30pm: Clinical Utility of Allospecific CD154+T-Cells in Children With Liver Or Intestine Transplantation (LTx, ITx)

K. Soltys, G. Bond, G. Mazariegos, C. Ashokkumar, K. Dirling, L. O'Toole, P. Kachmar, T. Hartle, D. Martin, C. Trautz, R. Sindhi.

5:30pm-7:30pm: De Novo Once-Daily Tacrolimus in Liver Transplantation: Long-Term Outcomes of a Single Center Cohort of 150 Patients

M. Gastaca, A. Valdivieso, J. Bustamante, P. Ruiz, J. Fernandez, A. Ventoso, M. Testillano, I. Palomares, P. Salvador, M. Prieto, A. Matarranz, M. Suarez, J. Ortiz de Urbina.

5:30pm-7:30pm: Does Smoking Lead to Increased Rates of Acute Cellular Rejection in Liver Transplant Recipients?

B. Rao,¹ D. Montezuma-Calvo,² K. Tosch,² S.-M. Jafri.²

5:30pm-7:30pm: Early Vs. Late Acute Antibody Mediated Rejection Among Renal Transplant Recipients in Terms of Its Response to Rituximab Therapy-Single Center Expereince

N. Nampoory, T. Alotaibi, O. Gheith, M. Halim, T. Mahmoud, P. Nair, M. Abdulmoneim, S. Alwaheb, R. Hasan.

5:30pm-7:30pm: Effects of Early Everolimus Use for Immunosuppression in Living Donor Liver Transplant Recipients- An Analysis of 215 Sequential Patients

A. Thorat, Y.-W. Hsieh, H.-R. Yang, C.-C. Yeh, T.-H. Chen, S.-C. Hsu, L.-B. Jeng.

5:30pm-7:30pm: Efficacy and Safety of Once-Daily Everolimus With Minimized Once-Daily Tacrolimus After Liver Transplantation

P. De Simone,¹ P. Carrai,¹ L. Coletti,¹ A. Precisi,² D. Campani,³ F. Filipponi.¹

5:30pm-7:30pm: Everolimus-Based Immunosuppression Is Associated With a Reduced Risk of New-Onset Malignancies After Liver Transplantation

P. De Simone,¹ P. Carrai,¹ L. Coletti,¹ D. Ghinolfi,¹ D. Campani,² F. Filipponi.¹

5:30pm-7:30pm: Forty-Seven Consecutive Simultaneous Liver-Kidney Transplants With Steroid Free Immunosuppression After Rabbit Antithymocyte Globulin Induction

D. Hall, V. Puri, S. Mabry, J. Vanatta, J. Eason.

5:30pm-7:30pm: Graft-Versus-Host Disease After Orthotopic Liver Transplantation: Multivariate Analysis of Risk Factors

M. Elfeki, P. Genco, S. Pungpapong, J. Nguyen, D. Harnois.

5:30pm-7:30pm: Hepatic T Cells Derived from Normothemic Machine Perfused Grafts Contained More Regulatory T Cells and Fewer Proinflammatory Cytokines Producing T Cells Than Those from Cold Storage Grafts

X. Huang, R. Ravikumar, C. Coussios, P. Srinivasan, N. Heaton, P. Friend, W. Jassem, Y. Ma.

5:30pm-7:30pm: Improved Renal Function Post-Liver Transplant With Earlier Everolimus Conversion

S. Lin,¹ M. Zimmerman,² V. Lewis,¹ S. Biggins,³ C. Ruller,⁴ I. Kam,⁴ T. Nydam.⁴

5:30pm-7:30pm: Incidence and Impact of De Novo Donor-Specific Anti-HLA Antibodies in ABO-Compatible Liver-Transplant Recipients

A. Del Bello,^1,2 N. Congy-Jolivet,^2,3,4 D. Milongo,¹ C. Guilbeau-Frugier,^2,5 L. Lavayssière,¹ F. Muscari,^2,6 L. Rostaing,^1,2,7 N. Kamar.^1,2,7

5:30pm-7:30pm: Incidence and Risk Factors for Infectious Complications in Liver Transplant Patients Converted to Everolimus

A. Islam,¹ J. DeVos,² L. Teeter,³ E. Graviss,³ S. Gordon-Burroughs,¹ A. Saharia,¹ C. Mobley,¹ A. Gaber,¹ R. Ghobrial.¹

5:30pm-7:30pm: Pharmacist-Led Renal-Sparing Conversion to Everolimus After Liver Transplantation

T. Horwedel,¹ L. Bowman,¹ W. Chapman,² J. Hagopian.¹

5:30pm-7:30pm: Plasmapharesis, Intravenous Immunoglobulin and Rituximab Successfully Treat Recurrent Progressive Familial Intrahepatic Cholestasis Type 2 (PFIC-2) After Liver Transplantation

H. Elsiesy,¹ F. Abaalkhail,¹ W. Alhamoudi,^1,2 H. Alhussaini,³ M. Alsebayel,¹ D. Broring,¹ M. Shagrani.¹

5:30pm-7:30pm: Renal Function Following Basiliximab Induction in Liver Transplant Recipients

J. Hagopian, T. Horwedel, L. Bowman, K. Collins, M. Doyle.

5:30pm-7:30pm: Results of ABO Incompatible Liver Transplantation Using a Simplified Protocol at a Single Institution

J. Lee,¹ J. Lee,¹ J. Lee,² M. Kim,¹ M. Ju,¹ G. Choi,¹ J. Choi,¹ S. Kim,¹ D. Joo.¹

5:30pm-7:30pm: Safety and Efficacy of Early Everolimus in De Novo Orthotopic Liver Transplantation

M. Gastaca,¹ I. Bilbao,² M. Jimenez,³ J. Bustamente,¹ C. Dopazo,² R. Gonzalez,³ R. Charco,² J. Santoyo,⁴ J. Ortiz de Urbina.¹

5:30pm-7:30pm: The Best Regimen With Rituximab for ABO-Incompatible Living Donor Liver Transplantation

H. Egawa,¹ K. Umeshita,² S. Uemoto.³

5:30pm-7:30pm: The Effect of Preformed and De Novo Donor-Specific Antibodies (DSA) in Acute Rejection (AR) After Liver Transplantation (LTX)

M. Koch,¹ M. Runnebaum,¹ M. Goebel,² H. Thude,¹ M. Sterneck,¹ M. Marget,² B. Nashan.¹

5:30pm-7:30pm: The Effects of Change in Body Mass Index on Morbidity and Mortality After Liver Transplantation

B. Kashat,² A. Prushani,¹ S. Jafri.¹

« View all sessions from the 2015 American Transplant Congress